Metabolic Profile and Weight Considerations
In selecting an adjunctive agent, the first decisive factor is the risk of weight gain and the patient’s current body mass index. Some drugs in this class are more likely to cause overweight. Therefore, existing metabolic history—such as hyperlipidemia, elevated glucose, pre‑diabetes, or type 2 diabetes—directly influences the choice. Another critical element is the risk of tardive dyskinesia, which varies slightly among agents.
Wellness insights
Social support networks of older adults before, during and after the COVID-19 pandemic
College Mental Health Crisis Shows Signs of Easing
Why Depression Subtypes Matter: 25 Years of Clinical Lessons
2027 Trials Target Severe Depression and PTSD with PsilocybinAddressing Anxious Depression
Patients with anxious depression—a phenotype considered more treatment‑resistant and slower to respond—require a more careful selection. An anxious depressive profile is marked by insomnia, worry, agitation, and cognitive symptoms. About 40 % of participants in lumateperone trials had anxious depression, with improvements typically seen within one to two weeks, though the latency is slightly longer for this subgroup.
Why Lumateperone Often Wins
For patients who refuse the risk of weight gain, lumateperone frequently becomes the preferred choice. Clinical studies show stable weight, with no significant changes compared to other adjunctive options. Its tolerability profile is favorable: no major shifts in weight, prolactin, or metabolic markers, and no increase in involuntary movements such as tardive dyskinesia, parkinsonism, or akathisia.
Prioritizing Non‑Negotiables
The initial approach involves asking the patient what aspects are non‑negotiable for them. The chosen agent should align with those priorities. If a patient struggles with basic self‑care, the clinician may opt for a different alternative.
The Therapeutic Relationship Matters
A practical message for colleagues emphasizes the importance of the therapeutic relationship. Clinicians are encouraged to build authentic connections, engage in honest conversations, and delve deeper when patients provide less information than usual. The ultimate goal remains remission, not merely a partial response. Accepting less than full remission is considered too risky, given the potential for relapse, functional decline, and safety concerns.
Beyond Traditional Antidepressants
Notably, the most robust remission data in MDD come from agents that act on glutamate, the brain’s primary excitatory neurotransmitter, rather than from conventional SSRIs, SNRIs, NDRIs, or tricyclics. Understanding glutamate’s role in various pathologies, including MDD, helps clinicians support patients on the path to wellness. The next episode, „Rapid‑Acting Antidepressants and the Psychedelic Debate,” will cover the latest rapid‑acting options, from glutamatergic agents to psychedelics.